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2587with the endothelial aortic surface when using the femoral
approach (a greater length of aorta is exposed to contact with
the catheter from femoral access than from radial access).
Furthermore, the arch and descending aorta compared with the
ascending aorta are the most common locations for complex
atherosclerotic plaques responsible for embolic phenomena (2).
Moreover, antiplatelet and anticoagulant regimens may increase
the risk of hemorrhagic transformation of unapparent embolic
events and favor their clinical presentation as hemorrhagic
events. These aspects may justify the design of a speciﬁc trial
using imaging pre/post studies to assess the incidence of thor-
acoabdominal embolic events during femoral versus radial
vascular access in PCI.
Finally, some methodological aspects should be pointed out.
First, bleeding outcomes in the study by Wimmer et al. (1)
cannot be considered rare events. Falsiﬁcation hypothesis has
been proposed to validate the identiﬁcation of rare adverse ef-
fects from population data, deﬁned as those occurring in <1 per
1,000 subjects (3). Second, the authors propose a single hy-
pothesis to falsify rather than several as recommended. Falsi-
ﬁcation hypothesis should be operationalized by testing
multiple implausible pre-speciﬁed hypotheses with the same
methods applied in the primary analysis. When many false
relationships are present, caution is warranted in the interpre-
tation of study ﬁndings. Finally, the mere absence of evidence
together with a low biological plausibility according to the state
of mechanistic knowledge at that time (or even less, the opinion
of experts) do not seem enough before proposing nonaccess
bleeding as a falsiﬁcation endpoint. There is a need to positively
demonstrate from properly designed studies that such an
observed effect is unlikely to be true. Otherwise, the generation
of knowledge outside the box and scientiﬁc progress may be
halted.
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Access, and Falsiﬁcation
Endpoints in Observational StudiesWe appreciate the interest and perspective of Dr. Valencia-Serrano
and colleagues on our exploration of the use of falsiﬁcation end-
points as a method of exploring the potential for residual con-
founding in observational comparative effectiveness studies (1). We
believe that such endpoints, akin to negative controls in experi-
mental methods, are an underutilized tool in the cardiovascular
data. We have used the examination of nonaccess site bleeding in
comparing transradial and transfemoral access in percutaneous
coronary intervention (PCI) as a simple illustrative example of how
such a method might be used in practice.
The utility of any falsiﬁcation endpoint rests on the assump-
tion that the treatments being compared should not differ with
respect to their inﬂuence on these endpoints. In this case, the
assumption is that the route of access for PCI, whether trans-
radial or transfemoral, should not inﬂuence the rate of nonaccess
site bleeding in a causal manner. Dr. Valencia-Serrano and
colleagues propose that the differences observed in the falsiﬁ-
cation endpoint in our analysis may, in fact, be due to a causal
relationship between the site of arterial access and nonaccess site
bleeding, mediated through the “hemorrhagic transformation of
clinically unapparent embolic infarctions” related to catheter
contact with the aorta during transfemoral procedures. Judging
the plausibility of potential biological explanations such as these,
versus the perhaps more banal explanation that the study suffers
from residual confounding, will most often require both clinical
subject matter expertise and an understanding of the limitations
of the methods used for statistical adjustment. In this particular
example, however, we beneﬁt from the existence of a large
randomized trial of transradial and transfemoral PCI in the ST-
segment elevation myocardial infarction population showing no
difference in nonaccess site bleeding (2), which serves as vali-
dation of this falsiﬁcation endpoint. More often, however, such a
randomized study will not exist to validate other potentially
useful endpoints. In the absence of such a study, we ﬁnd the
suggestion that investigators “positively demonstrate from
properly designed studies that such an observed effect [on the
falsiﬁcation endpoint] is unlikely to be true” leads to an ines-
capable tautology: a falsiﬁcation endpoint cannot be validated by
the very study it seeks to validate.
Finally, falsiﬁcation hypotheses and endpoints need not be
limited to studies examining rare events. Although the use of
multiple such endpoints may provide stronger evidence for or
against the likelihood of residual confounding, we do not believe
that it is simply a case of “more being better.” As these methods are
increasingly utilized by the research community, we will undoubt-
edly learn more about their merits and limitations. We are hopeful
that our brief investigation will promote further examination and
innovation in observational research methods through the use of
these and other techniques.
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Elephant in the Room
Look at the Red Blood CellsWe read with great interest the paper by Silvain et al. (1) on the
impact of red blood cell transfusion on platelet aggregation and in-
ﬂammatory response in anemic coronary and noncoronary patients.
The authors should be commended on a well-planned and well-
conducted study regarding a somewhat neglected aspect of
our therapeutic practice. We would like to point out, however, that
much of the discussion surrounding this and other related reports on
red blood cell transfusions in patients with heart disease is focused on
how they affect platelet function and other aspects of the coagulation
system. However, we should not miss the giant elephant in the
roomdthe red blood cells themselves. By transfusing blood to pa-
tients, we administer some billions of red blood cells that have been
submitted to a tedious procedure of collection, processing, and
storage in packed red blood cell units. This process is known to
produce alterations that lead to hemolysis and the formation
of erythrocyte microparticles (2). Free hemoglobin is an extremely
oxidative and vasospastic agent, and red blood cell microparticles
have been shown to be associated with endothelial dysfunction and
prothrombotic phenomena (3,4). As a result, red blood cells them-
selves (with no need to affect platelets in any signiﬁcant way) may
be a major determinant of transfusion adverse effects on cardiovas-
cular outcomes. This may also explain, at least in part, why the
authors found no connection between the storage duration of blood
units with platelet aggregation parameters: storage affects red blood
cells, which in turn may lead to the described unwanted cardiovas-
cular effects, in a way virtually unrelated to platelet function.*Georgios Giannopoulos, MD
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65:1164–73.ReplyDo Not Miss the
Elephant in the Room
Look at the Red Blood CellsWe thank Drs. Giannopoulos and Deftereos for their excellent
comments on the potential role of red blood cells (RBCs) as an
explanation for the excess of risk due to RBC transfusion.
We share their view on this point as data show an association
between cell-free, hemoglobin-based blood substitutes and the
risk of myocardial infarction and death (1) that is very similar to
the one found in registries between RBC transfusion and poor
outcomes in coronary patients. Unfortunately, we lack evidence on
the impact of cell-free hemoglobin through endothelial dysfunc-
tion and prothrombotic effects in patients receiving a RBC
transfusion.
We believe that activation of the P2Y purinergic receptors
is one of the relevant mechanisms, as demonstrated in our pre-
vious in vitro study (2). Indeed, platelet reactivity was increased
using different assays including light transmission aggregometry
to adenosine diphosphate (ADP), collagen, and vasodilator-
stimulated phosphoprotein phosphorylation platelet reactivity
index (VASP-PRI), highly speciﬁc tests suggesting a partial
activation of the P2Y12 receptors. We concluded that the
release of ADP from RBCs might be readily liberated in the
context of blood storage, thus representing a potential stimulus
for platelet activation and aggregation. The results of the
TRANSFUSION-2 study (3) support this hypothesis as the
impact on platelet reactivity was found only with tests exploring
